RxDoctor Payments Data

Andrea Olson

Adult Health · West Columbia, SCNPI 1316304769

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,369 of the $12,130 with a category attached, or 60.7%. Amgen accounts for 66.9% of it on its own, with 20 other manufacturers making up the rest. Among adult health clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,130in general payments, 2019–2025

Across 292 payments — averaging $41.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$8K
  • Novartis$2K
  • AstraZeneca$395
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$358
  • E.r. Squibb & Sons, L.L.C.$347
  • Alnylam Pharmaceuticals Inc.$310
  • plus $991 from 15 others

What the payments were for

  • Speaking & faculty fees$7,36961%
  • Food & beverage$4,74839%
  • Education$140%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,130 in reported general payments places this provider in the 95th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$217,804
Medicare patients
1,318
Services billed
5,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban932$946,259
VyndamaxTafamidis27$666,590
EntrestoSacubitril/Valsartan381$398,975
Repatha SureclickEvolocumab297$259,126
FarxigaDapagliflozin Propanediol156$139,908
XareltoRivaroxaban88$97,321
BrilintaTicagrelor55$44,999
JardianceEmpagliflozin41$34,697
MultaqDronedarone Hcl17$22,377
LivaloPitavastatin Calcium31$20,440
WegovySemaglutide14$18,170
Praluent PenAlirocumab26$17,858
Metoprolol Succinate1,013$17,537
VascepaIcosapent Ethyl26$16,352
Rosuvastatin Calcium765$15,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$162$1,612,850959 claims
NovartisEntresto$1,616$398,975381 claims
AstraZenecaFarxiga, Brilinta$395$184,906211 claims
Johnson & JohnsonXarelto$12$97,32188 claims
Kowa Pharmaceuticals America, Inc.Livalo$16$20,44031 claims
Novo NordiskWegovy$138$18,17014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 adult health providers in South Carolina.

Other adult health in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →